LincolnLand Agri Energy is an oil & energy company based out of United States.

Russtech Inc is a chemicals company based out of 5927 Canterbury Dr, Columbus, Georgia, United States.

MaC Venture Capital is the result of the merger between successful Los Angeles and Bay Area based Seed funds, Cross Culture Ventures and M Ventures. MaC Venture Capital is an early stage venture capital firm focused on finding ideas, technology, and products that can become infectious. We invest in technology companies that benefit from shifts in cultural trends and behaviors in an increasingly diverse global marketplace. We help entrepreneurs bring the future into focus to find their breakthrough moment. Our proven track record of 100+ investments has unlocked growth opportunities through capital, advisement, and relationship building. Our previous funds’ portfolios have returned capital to investors and continue to appreciate in value.

ALLENS PHARMASERV INC is a hospital & health care company based out of PO BOX 2208, YOUNGSTOWN, Ohio, United States.

60 years of excellence in development and production of custom coatings, paints and other finishes for industrial, commercial, and residential applications.

Best Shot Pet Products is a consumer goods company based out of 180 Commerce Blvd, Frankfort, KY, United States.

SPECIALTY ENTERPRISES, INC. is a warehousing company based out of 720 W. 121st Avenue, Westminster, Colorado, United States.

CERTIFIED FLUX SOLUTIONS LLC is a mining & metals company based out of PO BOX 372, MORGANTOWN, Kentucky, United States.

Eikonoklastes Therapeutics is developing a pipeline of disruptive new therapies that we can rapidly and relatively inexpensively advance from preclinical stage to clinical proof-of-concept and approval. We have now acquired our first two assets to treat devastating diseases that currently are severely inadequately treated. Our focus is on novel compounds that: 1) have platform capability where one molecule can treat multiple diseases with severe unmet clinical need, 2) will get preferred regulatory treatment due to the high unmet need and breakthrough potential, and 3) need relatively small clinical trials to achieve approval. Our 1st in class gene therapy (ET-101) has been engineered to overexpress Caveolin-1, which organizes & regulates synaptic receptors essential for neuromuscular signaling and function. It can treat a wide range of neurodegenerative diseases through precise, targeted overexpression of Caveolin-1 in neurons . We are also advancing a new generation of tissue factor (TF) therapies (ET-201) – therapeutics designed to target the cell surface receptor now known to be prevalent on solid tumor cells, tumor vasculature, and tumor stem cells, but absent on normal cells. By targeting these proteins which play a central role in the pathology of inflammation and angiogenesis, we can stop tumor growth, spread, and recurrence. Our first indications are neurodegenerative diseases and cancers with high unmet need and high mortality (e.g. ALS and triple negative breast cancer). A robust pipeline of additional indications (e.g. Alzheimer’s, Parkinson’s, etc. for ET-101; ovarian cancer, melanoma, etc. for ET-201) with severely inadequate treatment options will subsequently be pursued with these therapeutics.

We are a unique pharmacy offering compounding and specialty services. The P3 facility incorporates state-of-the-art equipment and is staffed with experienced professionals.

Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associated with reductions in inflammation and viral replication. INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon, and INV-102 is the first drug to show promise in preventing its long-term effects. There is no current FDA approved therapy for this injury. In September of 2020, Invirsa received a $29.6M BARDA award ($14.4M plus $15.2M in milestones) to support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other ocular injuries associated with DNA damage. The award covers development through Phase 3 clinical trials. Invirsa’s initial commercial focus for INV-102 will be infectious keratoconjunctivitis as there is no treatment for the viral form of this disease which comprises 80% of all cases. INV-102 has demonstrated clear efficacy in animal models of infectious conjunctivitis.

With over thirteen years of experience in the custom design and installation of high-tech electronics we continue to pride ourselves in customer satisfaction. Technologies of today are dynamic and interactive, allowing our staff to provide you with the latest and greatest of these technologies, will get you on the right track to simplify and enhance the daily tasks at your home or business. As a family-owned business our service and satisfaction extends from our family to yours to provide informative knowledge and practical technical solutions to keep you connected, keep you secure and keep you happy. From concept and design to installation our broad-range of products and services are sure to cover your every desire. Our state-of-the-art showroom is open Monday thru Friday 8AM to 5PM or by appointment. We are excited to show you what we have to offer!